Local versus systemic exposure, who needs a more careful assessment, and why breast risk is not one number.
Sep 2026 · Five minutes.
The details matter here more than almost anywhere else in midlife care.
Low-dose vaginal estrogen treats genitourinary syndrome of menopause: vaginal or vulvar dryness, burning, irritation, pain with sex, and some urinary symptoms. It comes as creams, tablets or inserts, and rings.
Low-dose local therapy produces far less systemic estrogen exposure than standard systemic hormone therapy, and generally does not require a progestogen for endometrial protection. Persistent or unexplained bleeding still requires evaluation.
Unlike hot flashes, which may improve with time, vulvovaginal and urinary tissue changes related to lower estrogen often persist or progress without treatment.
Moisturizers and lubricants help symptoms. Local prescription therapies act on tissue biology. Recurrent urinary tract infections, urgency, pain, or sexual discomfort deserve assessment, because treatment can meaningfully change quality of life.
For women with a history of breast cancer, nonhormonal options are usually considered first. When symptoms persist, low-dose vaginal estrogen may sometimes be considered through shared decision-making with the oncology and gynecology teams, particularly because systemic absorption is low.
That conversation differs according to tumor biology and use of therapies such as aromatase inhibitors. It belongs with your specialists.
A history of estrogen-sensitive cancer, unexplained vaginal bleeding, previous venous thromboembolism or stroke, coronary disease, significant liver disease, migraine pattern, gallbladder disease, smoking, metabolic risk, and strong family history may all influence whether hormone therapy is appropriate and which route is preferred.
A risk factor does not always mean an automatic no. It means the decision needs individualized clinical assessment.
Breast-cancer risk depends on baseline risk, age, duration of therapy, and the specific regimen. Estrogen alone and estrogen combined with a progestogen do not have identical evidence profiles. Different progestogens may also differ, though comparative long-term randomized data are limited.
You deserve an individualized discussion rather than the blanket statement that all hormone therapy either causes cancer or is completely safe.
There is no universal rule that therapy must stop at sixty or sixty-five. Continued treatment can be reasonable for persistent symptoms or bone protection when benefits continue to outweigh risks.
Periodic review should include symptom benefit, blood pressure and general health, new diagnoses or medications, bleeding, breast screening appropriate to your risk, and whether the dose and route still make sense. Routine hormone blood levels are generally not required to titrate standard therapy.
Hormones do not replace resistance training, adequate protein, cardiovascular exercise, sleep, nutrition, stopping smoking, blood-pressure and lipid management, bone-risk assessment, or attention to mental and sexual health.
Hormone therapy is one possible input into the larger midlife system. It is not the system.
What symptom or health goal are we treating? Why this hormone, dose, and route? Do I need endometrial protection? How do my breast, clotting, cardiovascular, migraine, liver, and bone history change the decision? What side effects or bleeding should prompt a call? When should we reassess?